AzTrials
AzTrials

Respiratory Tract InfectionsFINDpathNCT03312829

FINDpath: Fast I(n)Dentification of PATHogens

An observational study of Respiratory Tract Infections and Critical Illness, run by Hamilton Health Sciences Corporation at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Sepsis is the body-wide response to infection. People who develop sepsis have an increased risk of dying. One of the greatest challenges in sepsis is determining what is the pathogen (bacteria or virus for example) in a timely manner so the most specific antibiotics can be given to treat the infection. Read more about this study

Who is it for?
Ages 16 years and older
How many people
50 participants
Where
1 siteCanada
Study dates
May 2014to Jan 2016
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 16 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Adult Intubated ICU Patients

Who may be able to join

  • Age greater than 16yrs
  • ICU patients at the General site with a suspected tracheobronchitis or VAP
  • Ventilated for greater than 48 hours
  • No antibiotics for 24 hours prior to collection of specimens

Who cannot join

  • Hopeless prognosis
  • Have received antibiotics 24 hours prior to collection of specimens
  • Previously enrolled in FINDPATH

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Hamilton Health Sciences - General Site

    Hamilton, Ontario, L2L 2X2

Other trials in Canada

About this study

Official title: Team Sepsis: Fast I(n)Dentification of PATHogens (FINDPATH)

Sepsis is the body-wide response to infection. People who develop sepsis have an increased risk of dying. One of the greatest challenges in sepsis is determining what is the pathogen (bacteria or virus for example) in a timely manner so the most specific antibiotics can be given to treat the infection. Patients presenting to the hospital and the intensive care unit often have lung infections. In this study the investigators plan to develop new techniques to rapidly (less than 6 hours) identify bacteria growing in the airways of patients on ventilators. The investigators will obtain these samples by suctioning the airways (a routine procedure) and comparing the bacterial cultures grown by novel culture media with the usual techniques in the hospital microbiology laboratory. At the same time the investigators will collect a blood sample. This blood sample will be used to isolate the bacterial genetic material and use this to compare with bacteria grown on the culture media from the clinical and the research laboratory. The investigators will also collect information on the patient's course in hospital. These pilot study results will allow us to integrate this new technique into routine patient care.

Read the detailed description

The trial design is a pilot observational feasibility study within three intensive care units at the Hamilton General Hospital, which is composed of both medical and surgical patient populations where waived consent has been confirmed and approved by the Hamilton Integrated Research Ethics Board. The study sample will include 50 patients over the age of 16 that will be mechanically ventilated for greater than 48 hours with no antibiotic use for the past 24 hours and meet the Johanson Criteria for Ventilator Associated Pneumonia (VAP) as the gold standard for diagnosis still remain controversial. This Johanson criteria maintains patients must have 2 out of three criteria to be enrolled in the study and that criteria includes either a leukocyte count >12,000/mm³ , Fever >38.0ºC and/or a new onset of purulent endotracheal secretions or change in the character of sputum. Chest x-rays for examination of a new or progressing infiltrate will be assessed but will not be used for initial inclusion criteria but possibly in the conclusions when attempting to differentiate VAP from VAT.

Recruitment of eligible patients maintains the need for daily screening of patients which will be done primarily by myself as the co-investigator and from a research assistant through the secure hospital patient data system. However education of the frontline staff particularly nursing, respiratory therapists, physiotherapists and staff physicians who will have direct contact with potential subject is also essential for successful recruitment, coordination and timing of enrollment. I will create and hold education sessions for all frontline staff outlining the purpose of the study, patient enrollment criterion and proper sample collection procedures as well as continual bedside education throughout the course of the study to ensure all staff will have the information to identify potential study patients.

Once patients are identified as meeting criteria for enrollment, the research assistant will be notified at which time the frontline staff will retrieved a premade package for the sample collection. Using a sterile catheter and a clean technique, two separate tracheal aspirates will be acquired from the subject and placed in their specialized clinical or research sputum trap. To acquire two samples, sterile saline irrigation will be permitted and if needed the splitting of the specimen into the separated collection traps. Concurrently a tube of blood as well as one set of blood cultures from an established indwelling access (either central line, arterial line or peripheral blood draw) will be drawn. Clinical lab labels will be placed on one sputum sample and the set of blood cultures and sent routinely to the microbiology lab. The research lab bag will contain the second sputum sample and blood tube labelled with patient identification number and the time of sample collection. To ensure the ability of culturing for anaerobic bacteria in the research laboratory, an anaerobic pack will be placed in the research sample bag with the sputum sample and blood tube as well as a damp paper towel. The sample bag will then be voided of air and sealed. The research bag is labelled as well with patient identification number and date/time of sample collection which is then sent to the clinical microbiology lab. The clinical laboratory is then notified of the incoming research sample which will need to be transported to the research laboratory via established laboratory transportation protocols. Once the sample is sent, the co-investigator is notified again and clinical data (leukocytes, hemoglobin, platelets, arterial blood gases, temperature, Glasgow coma scale, oxygen requirements, high/low respiratory rate, heart rate, and blood pressure) for the day of collection and for the following six days including complete ICU antibiotic usage, extubation date and final patient outcome after 30 days can be collected and entered into a secure RedCap database. Communication to the research laboratory will be the responsibility of the co-investigator to ensure samples have arrived and can be plated in the time set out within the study protocol. Transportation of the samples are available from 0700 until 2000 Monday through Sunday so identification of potential enrollment , and collection of samples will be encouraged during these times to ensure successful arrival and processing of samples at the research laboratory.

Medical subject headings
Respiratory Tract Infections, Critical Illness

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of eligible patients recruited by front line respiratory and nursing staff

    Staff identify and enrolled 80% of eligible patients

    Measured: 12 months

Secondary outcomes (1)
  1. Correlation between clinical lab and research laboratory for pathogen identification

    What pathogens are identified by the research lab that are not cultured in the clinical laboratory

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Oct 2017
  2. Study startMay 2014
  3. Primary completionDec 2015
  4. Study completionJan 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
50 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03312829
Sponsor's protocol ID
FINDpath14
Acronym
FINDpath
Status last verified
Oct 2017
First submitted
29 Aug 2014
Last updated
18 Oct 2017
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided: analysis in progress

Questions about this trial

What is this clinical trial studying?

An observational study of Respiratory Tract Infections and Critical Illness, run by Hamilton Health Sciences Corporation at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Oct 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of eligible patients recruited by front line respiratory and nursing staff (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2017.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in